Pharmaceutical Executive-03-01-2019

Pharmaceutical Executive

Patients is a Virtue

March 14, 2019

Features

39

3

Providers of patient service solutions for pharma companies share insights on the nuances of the "consumer' connection and the shifts taking place in making patient-centric programs and tools more alive for patients.

What Does Patient Centricity Look Like?

March 14, 2019

From the Editor

39

3

That often-muddled picture is becoming increasingly clearer in the patient and business context as different ways in which patients, patient communities, advocacy, and pharma engage each other converge.

John Crowley: Living the Mission

March 14, 2019

Features

39

3

Amicus Therapeutics CEO John Crowley, whose biotech journey and quest to cure two of his kids of a rare genetic disease is well chronicled, discusses the growing role of the patient-centered view in company culture-not just in adding “deeper meaning” to drug development, but in building patient advocacy into everyday business practice and strategy.

Research Bonds Strengthen

March 14, 2019

Features

39

3

Efforts to collaborate around patient engagement in every phase of product development are illustrating the growing relationship between disease advocacy groups and industry.

Pharm Exec Joins MJH Portfolio

March 07, 2019

In the News

39

3

Michael J. Hennessy Jr., president of MJH Associates‚ Inc., answers questions about the acquisition of UBM Life Sciences media brands and his company’s perspective on the evolving biopharma landscape.

Pinpointing Performance of Key Access Activities

March 06, 2019

Features

39

3

While market access functions have evolved, the same can’t be said for measures used to gauge the contribution of these activities on overall business. To that end, an industry working group has developed a common framework focused on the most relevant access performance metrics (APMs).

Pharmaceutical Executive, March 2019 Issue (PDF)

March 01, 2019

Issue PDF

39

3

Click the title above to open the Pharmaceutical Executive March 2019 issue in an interactive PDF format.

Country Report: France

March 01, 2019

Special Sponsored Section

39

3

After a prolonged period of relative stagnation, the strategically influential, clinically rich French life sciences market suddenly seems to be rediscovering its mojo-thrusting the pharma and medtech sectors into the spotlight.